Nuzzi G, Venturini I, De Gregorio M, Arsenio L, Maraini G
Institute of Ophthalmology, University of Parma, Italy.
Acta Ophthalmol Scand. 1997 Feb;75(1):41-3. doi: 10.1111/j.1600-0420.1997.tb00247.x.
Vitreous fluorophotometry was used to investigate the effect of Bendazac lysine on the blood retinal barrier in 12 insulin-dependent diabetics with mild background retinopathy. The study was a randomized, double blind, cross-over trial, drug versus Placebo. Each treatment period was of 4 months. The vitreous penetration coefficient was reduced by 21% (95% c.i. 12, 30; p = 0.001) by treatment with respect to Placebo.
采用玻璃体荧光光度测定法，研究了赖氨酸苄达酸对12例患有轻度背景性视网膜病变的胰岛素依赖型糖尿病患者血视网膜屏障的影响。该研究为随机、双盲、交叉试验，比较药物与安慰剂。每个治疗期为4个月。与安慰剂相比，治疗使玻璃体渗透系数降低了21%（95%置信区间为12, 30；p = 0.001）。
